Midostar 25mg Capsule Supplier USA | Pharmaceutical Exporter from India

Midostar 25mg Capsule: Precision Midostaurin Therapy for AML and Mast Cell Disorders

Are you looking for a reliable Midostar 25 mg capsule exporter from India? Ernest Oncology, a dedicated division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced hematological treatments. We offer a high-authority, regulatory-compliant supply chain serving the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that life-saving oncology medications reach healthcare providers with pharmaceutical-grade integrity and global logistics expertise.

Detailed Product Overview: What is Midostar 25mg?

Midostar 25mg is an oral soft gelatin capsule containing the active pharmaceutical ingredient Midostaurin. Classified as a multitargeted kinase inhibitor, it is designed to disrupt the signaling pathways that allow certain types of cancer and blood disorders to thrive. Midostar is a cornerstone of precision medicine, specifically targeting proteins that drive the overproduction of abnormal cells in the bone marrow and blood.

The 25mg strength is the standardized dosage unit, allowing for precise titration in complex treatment regimens. It is manufactured by leading Indian pharmaceutical houses like Zydus Lifesciences, ensuring world-class quality and efficacy.

Primary Therapeutic Indications: 

Midostar 25mg is clinically indicated for the management of:

1. Acute Myeloid Leukemia (AML): Specifically for newly diagnosed adult patients who are FLT3 mutation-positive. It is used in combination with standard induction (cytarabine and daunorubicin) and consolidation chemotherapy.

2. Aggressive Systemic Mastocytosis (ASM): A rare disorder where too many mast cells build up in internal organs.

3. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN).

4. Mast Cell Leukemia (MCL): A highly aggressive form of mast cell disease.

Mechanism of Action: How Midostar 25 mg Works: 

Midostar 25 mg functions by inhibiting several receptor tyrosine kinases involved in cell proliferation and survival:

• FLT3 Inhibition: In patients with AML, it blocks the mutated fms-like tyrosine kinase 3 (FLT3) receptor. This stops the "growth signal" that tells leukemic cells to multiply uncontrollably.

• KIT Inhibition: It targets the proto-oncogene c-KIT. By blocking mutant KIT receptors, Midostar reduces the proliferation and survival of abnormal mast cells in systemic mastocytosis.

• Multi-Kinase Blockade: It also inhibits other kinases such as PDGFR and VEGFR, further disrupting the tumor microenvironment.

Administration and Safety Guidelines:

• Dosage: Typically taken as 50mg (two 25mg capsules) or 100mg (four 25mg capsules) twice daily, depending on the indication.

• Food Requirement: It is critical to take Midostar with food to minimize gastrointestinal side effects like nausea and vomiting.

• Instruction: Swallow capsules whole with a glass of water. Do not break, crush, or chew the softgel.

• Safety Monitoring: Patients require regular monitoring of complete blood counts (CBC), heart function (monitoring for QT prolongation), and lung health.

• Avoidances: Do not consume grapefruit or grapefruit juice, as it can significantly increase the concentration of the drug in the blood.

Why Source Midostar 25 mg from Ernest Oncology?

• Direct Exporter from India: We provide direct access to GMP-certified manufacturing, ensuring 100% product authenticity and competitive bulk pricing.

• Logistics Mastery: Expertise in international shipping to the USA, UK, UAE, Australia, and South Africa, including full documentation and customs support.

• Bulk Supply Stability: We maintain a consistent inventory of Midostar 25 mg to ensure patient treatment cycles remain uninterrupted.

• B2B Excellence: We specialize in supplying international pharmaceutical wholesalers, oncology hospitals, and government health tenders.